Small Molecules
4 September 2014
New data presented at WCCS confirm high long-term efficacy of Picato® in patients with actinic keratosis4 September 2014
Nosopharm shares scientific data on Odilorhabdins, a novel antibacterial class with the potential to combat antibiotic resistance3 September 2014
Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years of age3 September 2014
Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic3 September 2014
Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial in Canada of RhopressaTM in Patients with Glaucoma3 September 2014
Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes3 September 2014
Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome3 September 2014
Aerpio Therapeutics Announces Publication of Preclinical Data on AKB-9778 for Common Eye Diseases3 September 2014
ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis3 September 2014
MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome3 September 2014
Birken Announces Positive Results of Phase III Trials with Oleogel-S10 for Accelerated Wound Healing in Patients with Partial Thickness Wounds2 September 2014
Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Adolescents With ADHD2 September 2014
Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events2 September 2014
Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-1152 September 2014
Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea2 September 2014
SAGE Therapeutics Presents New Preclinical Data on SAGE-217 at Eilat Conference on New Anti-Epileptic Drugs2 September 2014
Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention2 September 2014
Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate CancNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports